The Airway Microbiota Modulates Effect of Azithromycin Treatment for Episodes of Recurrent Asthma-like Symptoms in Preschool Children: A Randomized Clinical Trial

Rationale Childhood asthma is often preceded by recurrent episodes of asthma-like symptoms, which can be triggered by both viral and bacterial agents. Recent randomized controlled trials have shown that azithromycin treatment reduces episode duration and severity through yet undefined mechanisms. Ob...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2021-07, Vol.204 (2), p.149-158
Main Authors: Thorsen, Jonathan, Stokholm, Jakob, Rasmussen, Morten Arendt, Mortensen, Martin Steen, Brejnrod, Asker Daniel, Hjelmsø, Mathis, Shah, Shiraz, Chawes, Bo, Bønnelykke, Klaus, Sørensen, Søren Johannes, Bisgaard, Hans
Format: Article
Language:English
Subjects:
Airway management
Antibiotics
Asthma
Children & youth
Clinical trials
Microbiota
Pediatrics
Preschool children
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rationale Childhood asthma is often preceded by recurrent episodes of asthma-like symptoms, which can be triggered by both viral and bacterial agents. Recent randomized controlled trials have shown that azithromycin treatment reduces episode duration and severity through yet undefined mechanisms. Objectives Here, we studied the influence of the airway microbiota on the effect of azithromycin treatment during acute episodes of asthma-like symptoms. Methods Children from the Copenhagen Studies on Asthma in Childhood 2010 (COPSAC2010) cohort with recurrent asthma-like symptoms aged 12-36 months were randomized during acute episodes to azithromycin or placebo as previously reported. Prior to randomization, hypopharyngeal aspirates were collected and examined by 16S rRNA gene amplicon sequencing. Measurements and Main Results In 139 airway samples from 68 children, episode duration after randomization was associated with microbiota richness (7.5% increased duration per 10 additional Operational Taxonomic Units (OTUs), 95% confidence interval [1%;14%], p=0.025), with 15 individual OTUs (including several Neisseria and Veillonella), and with microbial pneumotypes defined from weighted UniFrac distances (longest durations in a Neisseria-dominated pneumotype). Microbiota richness before treatment increased the effect of azithromycin by 10% per 10 additional OTUs, and more OTUs were positively vs. negatively associated with increased azithromycin effect (82 vs. 58, p=0.0032). Furthermore, effect modification of azithromycin was found for 5 individual OTUs (3 increased and 2 decreased the effect, q
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.202008-3226OC